These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31705590)

  • 21. Dabrafenib and trametinib for the treatment of non-small cell lung cancer.
    Kelly RJ
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1063-1068. PubMed ID: 30198802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
    J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trametinib for progressive pediatric low-grade gliomas.
    Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
    J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical timolol: An effective treatment option for agminated pyogenic granuloma.
    McGinness A; Gillam A; Yeh I; Mathes EF
    Pediatr Dermatol; 2018 Sep; 35(5):e300-e303. PubMed ID: 29961974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case series showing the efficacy of 5-aminolaevulinic acid photodynamic therapy for epidermal growth factor receptor inhibitor-induced paronychia and pyogenic granuloma-like lesions.
    Panariello L; Donnarumma M; Cinelli E; Fabbrocini G
    Br J Dermatol; 2019 Mar; 180(3):676-677. PubMed ID: 30298920
    [No Abstract]   [Full Text] [Related]  

  • 28. Xanthogranulomatous reaction to trametinib for metastatic malignant melanoma.
    Min MS; Yao J; Chee N; Sapadin AN; Shim-Chang H
    Cutis; 2018 Oct; 102(4):283-286. PubMed ID: 30489553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings?
    Egan G; Hamilton J; McKeown T; Bouffet E; Tabori U; Dirks P; Bartels U
    J Pediatr Hematol Oncol; 2020 May; 42(4):e248-e250. PubMed ID: 30676433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.
    Nardin C; Colas M; Badoz M; Roche-Kubler B; Meneveau N; Puzenat E; Aubin F
    Eur Heart J; 2017 Jul; 38(27):2151. PubMed ID: 28329154
    [No Abstract]   [Full Text] [Related]  

  • 31. Ocular toxicity due to Trametinib and Dabrafenib.
    Sarny S; Neumayer M; Kofler J; El-Shabrawi Y
    BMC Ophthalmol; 2017 Aug; 17(1):146. PubMed ID: 28818062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noninvasive Treatment of Pyogenic Granulomas in Young Children with Topical Timolol and Trichloroacetic Acid.
    Chiriac A; Birsan C; Podoleanu C; Moldovan C; Brzezinski P; Stolnicu S
    J Pediatr; 2016 Feb; 169():322-322.e1. PubMed ID: 26589346
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
    N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
    White PS; Pudusseri A; Lee SL; Eton O
    Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors.
    Reinhard R; Gebhardt C; Schmieder A; Umansky V; Utikal J
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e375-e377. PubMed ID: 28222227
    [No Abstract]   [Full Text] [Related]  

  • 38. The Role of Topical Timolol in the Treatment of Infantile Hemangiomas: A Systematic Review and Meta-analysis.
    Khan M; Boyce A; Prieto-Merino D; Svensson Å; Wedgeworth E; Flohr C
    Acta Derm Venereol; 2017 Nov; 97(10):1167-1171. PubMed ID: 28421234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.
    Consoli F; Manganoni AM; Grisanti S; Petrelli F; Venturini M; Rangoni G; Guarneri F; Incardona P; Vermi W; Calzavara Pinton PG; Berruti A
    PLoS One; 2019; 14(4):e0214884. PubMed ID: 30939167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trametinib for patients with advanced melanoma.
    Masuda S; Izpisua Belmonte JC
    Lancet Oncol; 2012 Oct; 13(10):e409; author reply e409-10. PubMed ID: 23026823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.